貝達藥業(300558.SZ):完成以8000萬美元認購Xcovery新發行的F輪優先股
格隆匯3月4日丨貝達藥業(300558.SZ)公佈,此前披露,公司第三屆董事會第二十四次會議審議通過《關於認購 Xcovery 新發行F輪優先股的議案》,同意公司通過全資子公司貝達投資(香港)有限公司以不超過5.8129美元每股的價格認購控股子公司Xcovery Holdings,Inc. (“Xcovery”)新發行F輪優先股,按持股比例認購金額及超額認購金額合計不超過8000萬美元,此次認購事項未構成關聯交易及重大資產重組。
公司已根據《認購協議》的約定支付了8000萬美元的股權認購款,股份交割已辦結,公司現持有Xcovery 4779.4585萬股,持股比例為69.53%。此次投資已取得對外直接投資(ODI)備案。
貝達藥業參與此次認購Xcovery新發行的F輪優先股,有利於支持Xcovery的進一步發展,充分發揮其業務平台作用,落實公司海外發展戰略,同時補充Xcovery日常研發和運營資金,加快推進恩沙替尼項目儘快上市。
目前恩沙替尼項目的全球多中心III期臨牀試驗正在推進中,同時公司也在加緊落實向美國食品藥品監督管理局(FDA)提交恩沙替尼新藥上市申請(NDA)的申報準備工作,新藥獲批的時間以及後續產品上市後的銷售情況等存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.